Public Source Meta-databases — Applications and Benefits
The benefits of applying public source meta-databases as part of an integrated literature modeling strategy include:
- The ability to make explicit quantitative assessments between competing treatments when no direct within-study comparisons are available
- The ability to predict clinical outcomes for NCEs even when no new clinical data are collected (e.g., at unstudied doses or the extrapolation of steady-state effect from early short-duration dose ranging trials)
- The ability to bridge preclinical-to-clinical or biomarker-to-clinical relationships within a common therapeutic class
- Greater objectivity when predicting and inferring an NCE’s critical efficacy/safety/tolerability attributes (e.g., comparison of NCE attributes and uncertainty with competing therapies and draft launch label targets)
These benefits mean higher drug development productivity, improved clinical quality and commercial performance of new therapies, as well as greater transparency for decision-making throughout the development team and across the organization.